Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Summary
Third Opinion Trial Synopsis:
Doctors conducted a small study to see if patients with a type of cancer called multiple myeloma who had received a specific type of treatment called autologous stem cell transplant and had no remaining cancer cells could safely stop taking medicine to prevent their cancer from coming back.
Doctors conducted a small study to see if patients with a type of cancer called multiple myeloma who had received a specific type of treatment called autologous stem cell transplant and had no remaining cancer cells could safely stop taking medicine to prevent their cancer from coming back.
*Third Opinion AI Generated Synopsis
Trial Summary
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
